TGF-β1 mediates the radiation response of prostate cancer

Journal of Molecular Medicine

Volumn 93, Issue 1, 2014, Pages 73-82

  Wu, Chun Te ^a,b   Hsieh, Ching Chuan ^a,b   Yen, Tzu Chen ^a,b   Chen, Wen Cheng ^a,b   Chen, Miao Fen ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Irradiation; Prostate cancer; Regulatory Tcells; TGF 1

Indexed keywords

DNA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL DEATH; CLONOGENIC ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; LETHAL DOSE; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; RADIATION RESPONSE; RADIOSENSITIVITY; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; IMMUNOLOGY; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84926672617     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-014-1206-6     Document Type: Article

References (45)

1. Alongi F, De Bari B, Campostrini F, Arcangeli S, Matei DV, Lopci E, Petralia G, Bellomi M, Chiti A, Magrini SM et al (2013) Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: a review. Crit Rev Oncol Hematol 88: 550-563.
2. Wu CT, Chen WC, Liao SK, Hsu CL, Lee KD, Chen MF (2007) The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy. Endocr Relat Cancer 14: 633-643.
3. Tombal B (2011)What is the pathophysiology of a hormone-resistant prostate tumour? Eur J Cancer 47(Suppl 3): S179-S188.
4. Kuonen F, Secondini C, Ruegg C (2012) Molecular pathways: Emerging pathways mediating growth, invasion, and metastasis of tumors progressing in an irradiated microenvironment. Clin Cancer Res 18: 5196-5202.
5. Bernier J, Fuks Z (2004) Advances in translational radiation oncology: from molecular signaling to cancer cure. Int J Radiat Oncol Biol Phys 58: 305-306.
6. Atkinson MJ (2013) Radiation treatment effects on the proteome of the tumour microenvironment. Adv Exp Med Biol 990: 49-60.
7. Drabsch Y, ten Dijke P (2012) TGF-beta signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev 31: 553-568.
8. Katsuno Y, Lamouille S, Derynck R (2013) TGF-beta signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol 25: 76-84.
9. Li MO, Flavell RA (2006) TGF-beta, T-cell tolerance and immunotherapy of autoimmune diseases and cancer. Expert Rev Clin Immunol 2: 257-265.
10. Fuxe J, Karlsson MC (2012) TGF-beta-induced epithelialmesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol 22: 455-461.
11. Yang L (2010) TGFbeta and cancer metastasis: an inflammation link. Cancer Metastasis Rev 29: 263-271.
12. Saunier EF, Akhurst RJ (2006) TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets 6: 565-578.
13. Oleinika K, Nibbs RJ, Graham GJ, Fraser AR (2013) Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol 171: 36-45.
14. Hardee ME, Marciscano AE, Medina-Ramirez CM, Zagzag D, Narayana A, Lonning SM, Barcellos-Hoff MH (2012) Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-beta. Cancer Res 72: 4119-4129.
15. Bouquet F, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, Babb JS, Lonning SM, DeWyngaert JK, Formenti SC et al (2011) TGFbeta1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res 17: 6754-6765.
16. Wikstrom P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A (1998) Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 37: 19-29.
17. Wu CT, Hsieh CC, Lin CC, Chen WC, Hong JH, Chen MF (2012) Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells. J Mol Med (Berl) 90: 1343-1355.
18. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A (2003) CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: Possible involvement of regulatory T cells in disease progression. Cancer 98: 1089-1099.
19. Shiloh Y (2003) ATM and related protein kinases: Safeguarding genome integrity. Nat Rev Cancer 3: 155-168.
20. Ewan KB, Henshall-Powell RL, Ravani SA, Pajares MJ, Arteaga C, Warters R, Akhurst RJ, Barcellos-Hoff MH (2002) Transforming growth factor-beta1 mediates cellular response to DNA damage in situ. Cancer Res 62: 5627-5631.
21. Sak A, Stuschke M (2010) Use of gammaH2AX and other biomarkers of double-strand breaks during radiotherapy. Semin Radiat Oncol 20: 223-231.
22. Sharma S, Sharma MC, Sarkar C (2005) Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology 46: 481-489.
23. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454.
24. Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, Zhang Q, Lonning S, Teicher BA, Lee C (2007) Tumor evasion of the immune system by converting CD4+CD25-T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 178: 2883-2892.
25. Kachikwu EL, Iwamoto KS, Liao YP, DeMarco JJ, Agazaryan N, Economou JS, McBride WH, Schaue D (2011) Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys 81: 1128-1135.
26. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L, Pisa P (2006) CD4+CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177: 7398-7405.
27. Flammiger A, Weisbach L, Huland H, Tennstedt P, Simon R, Minner S, Bokemeyer C, Sauter G, Schlomm T, TrepelM (2013) High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. Eur J Cancer 49: 1273-1279.
28. Cretney E, Kallies A, Nutt SL (2013) Differentiation and function of Foxp3(+) effector regulatory T cells. Trends Immunol 34: 74-80.
29. Qinfeng S, DepuW, Xiaofeng Y, ShahW, Hongwei C, YiliW (2013) In situ observation of the effects of local irradiation on cytotoxic and regulatory T lymphocytes in cervical cancer tissue. Radiat Res 179: 584-589.
30. Tran DQ (2012) TGF-beta: the sword, the wand, and the shield of FOXP3(+) regulatory T cells. J Mol Cell Biol 4: 29-37.
31. Du S, Barcellos-Hoff MH (2013) Tumors as organs: biologically augmenting radiation therapy by inhibiting transforming growth factor β activity in carcinomas. Semin Radiat Oncol 23: 242-251.
32. Muller WJ, Swanson I (2013) Orthotopic and Ectopic Models of Metastasis Experimental and Clinical Metastasis pp 227-236.
33. Knox JD, Mack CF, Powell WC, Bowden GT, Nagle RB (1993) Prostate tumor cell invasion: a comparison of orthotopic and ectopic models. Invasion Metastasis 13: 325-331.
34. Elliott RL, Blobe GC (2005) Role of Transforming Growth Factor Beta in Human Cancer. J Clin Oncol 23: 2078-2093.
35. Ivanovic V, Melman A, Davis-Joseph B, ValcicM, Geliebter J (1995) Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. Nat Med 1: 282-284.
36. Zavadova E, Vocka M, Spacek J, Konopasek B, Fucikova T, Petruzelka L (2014) Cellular and humoral immunodeficiency in breast cancer patients resistant to hormone therapy. Neoplasma 61: 90-98.
37. Reis ST, Pontes-Júnior J, Antunes AA, Sousa-Canavez JM, Abe DK, Cruz JA, Dall'oglio MF, Crippa A, Passerotti CC, Ribeiro-Filho LA et al (2011) Tgf-β1 expression as a biomarker of poor prognosis in prostate cancer. Clinics (Sao Paulo) 66: 1143-1147.
38. Shariat SF, Walz J, Roehrborn CG, Montorsi F, Jeldres C, Saad F, Karakiewicz PI (2008) Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy. J Urol 179: 1593-1597.
39. Andarawewa KL, Costes SV, Fernandez-Garcia I, ChouWS, Ravani SA, Park H, Barcellos-Hoff MH (2011) Lack of radiation dose or quality dependence of epithelial-to-mesenchymal transition (EMT) mediated by transforming growth factor beta. Int J Radiat Oncol Biol Phys 79: 1523-1531.
40. Schaue D, Ratikan JA, Iwamoto KS, McBride WH (2012) Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 83: 1306-1310.
41. Baba J, Watanabe S, Saida Y, Tanaka T, Miyabayashi T, Koshio J, Ichikawa K, Nozaki K, Koya T, Deguchi K et al (2012) Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia. Blood 120: 2417-2427.
42. Lissoni P, Brivio F, Fumagalli L, Messina G, Meregalli S, Porro G, Rovelli F, Vigorè L, Tisi E, D'Amico G (2009) Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients. Anticancer Res 29: 1847-1852.
43. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, WahlSM (2003) Conversion of peripheral CD4+CD25-naive Tcells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198: 1875-1886.
44. Nicolini A, Rossi G, Ferrari P, Carpi A (2014) Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer. Biomed Pharmacother 68: 171-178.
45. Smith AL, Robin TP, Ford HL (2012) Molecular pathways: Targeting the TGF-β pathway for cancer therapy. Clin Cancer Res 18: 4514-4521.